Key result
Qiliqiangxin (QLQX) decreases NT-proBNP levels, improves functional outcomes, and reduces cardiovascular mortality and hospitalization in heart failure patients receiving standard medication.
Why the study?
QLQX has shown therapeutic potential in HF through multifaceted mechanisms, warranting a synthesis of preclinical and clinical evidence.
Does Qiliqiangxin improve clinical and functional outcomes in patients with heart failure?
Does Qiliqiangxin improve clinical and functional outcomes in patients with heart failure?
Qiliqiangxin, a traditional Chinese medicine, shows therapeutic potential in heart failure by improving functional outcomes and reducing cardiovascular mortality and hospitalization when added to standard therapy.
QLQX may support adjunctive HF exploration; leaves open need for large RCTs before any practice consideration.
Qiliqiangxin (QLQX), a traditional Chinese medicine (TCM) formulation, has shown therapeutic potential in heart failure (HF) through its multifaceted mechanisms. This review synthesizes preclinical and clinical evidence, highlighting the ability of QLQX to modulate cardiac remodeling, inflammation, fibrosis, and neurohormonal activation. Preclinical studies have revealed that the bioactive components of QLQX target peroxisome proliferator-activated receptor γ, mitochondrial metabolism, and calcium transport. Clinically, QLQX capsule decreases N-terminal pro B-type natriuretic peptide levels and improves functional outcomes in chronic HF. The QUEST trial has indicated diminished cardiovascular mortality and hospitalization in patients with HF and reduced ejection fraction receiving QLQX treatment in addition to standard medication. Challenges include standardization of TCM formulations and mechanistic clarity. Future research should prioritize rigorous trials, comparative studies with conventional therapies, and integration of TCM into evidence-based practice.
No takes yet. Share an insight, caveat, or question.
Cheang et al. (2025) conducted a review in Heart failure. Qiliqiangxin (QLQX) vs. Standard medication was evaluated. Qiliqiangxin (QLQX) decreases NT-proBNP levels, improves functional outcomes, and reduces cardiovascular mortality and hospitalization in heart failure patients receiving standard medication.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: